Shots:

• The US FDA has approved J&J medtech’s VARIPULSE PFA platform for treating drug refractory paroxysmal Atrial Fibrillation (AFib)
• Approval was based on the admIRE trial that showed of 291 patients, 100% attained acute procedural success, with 98% achieving first-pass isolation per vein and peak primary effectiveness was seen in 85% with 73-96 applications per vein. 12mos. data was published in Circulation
• The platform combines PFA therapy and advanced CARTO 3 mapping. It enables precise ablation with real-time catheter visualization, minimal to zero-fluoro workflows with ICE ultrasound. Its single-transseptal workflow supports efficient and predictable procedures for both routine and complex AFib cases

Ref: Johnson & Johnson | Image: Johnson & Johnson 

Related News:- Johnson & Johnson’s Edurant Receives the EC Approval for Expanded Use as HIV-1 Therapy in Pediatric Individualshttps://pharmashots.com/19818/johnson-johnson-s-edurant-receives-the-ec-approval-for-expanded-use-as-hiv-1-therapy-in-pediatric-individuals

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com